Categories
Change Password!
Reset Password!
Acotiamide appears effective and well-tolerated in children with functional dyspepsia, showing symptom improvement across all subtypes.
A new study suggests that acotiamide, a prokinetic agent commonly used in adults, may also be beneficial in easing the symptoms of functional dyspepsia (FD) in children and adolescents.
While acotiamide’s efficacy is well-established in adults—particularly for postprandial distress syndrome (PDS)—its usage in pediatric populations has remained largely unexplored. To investigate this gap, researchers retrospectively analyzed the medical records of 33 children under the age of 16 who were diagnosed with FD and treated with acotiamide. Patients were categorized into FD subtypes: epigastric pain syndrome (EPS), PDS, or an overlap of both.
One month after initiating treatment, 57.6% (19/33) of patients reported symptom relief. Subtype-specific response rates were 63.6% for EPS, 20.0% for PDS, and 66.7% for those with overlapping symptoms. Although differences among subtypes did not reach statistical significance (p=0.213), the data illustrated a trend towards greater benefit in EPS and overlap cases compared to isolated PDS.
Importantly, acotiamide was generally well-tolerated. Only 2 patients discontinued the medication due to worsening abdominal pain, and no serious adverse events were noted throughout the study period. This favorable safety profile reinforces acotiamide’s potential role in pediatric FD care. These findings, while preliminary, mirror previously reported outcomes in adult populations and offer early support for the off-label use of acotiamide in children.
Pediatric Gastroenterology, Hepatology & Nutrition
Efficacy of Acotiamide in Pediatric Patients with Functional Dyspepsia
Keinosuke Hizuka et al.
Comments (0)